


CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof




(I)

wherein

- R^{1a}, at each occurrence, is independently selected from the group consisting of C₁₋₄alkyl, hydrogen, and C₁₋₄haloalkyl;
- R^{1b}, at each occurrence, is independently selected from the group consisting of C(O)N(R^{1c})–C₁₋₆alkylene–CO₂H, C(O)OH, C(O)N(R^{1c})CHR^{1e}CO₂H, C(O)N(R^{1c})–C₁₋₆alkylene–C(O)OC₁₋₄alkyl, C(O)OC₁₋₄alkyl, C(O)N(R^{1c})CHR^{1e}C(O)OC₁₋₄alkyl, hydrogen, C₁₋₄alkyl, and C₁₋₄haloalkyl;
- R^{1c}, at each occurrence, is independently hydrogen or C₁₋₄alkyl;
- R^{1e}, at each occurrence, is independently –C₁₋₄alkylene–CO₂H, –C₁₋₄alkylene–CONH₂, or –C₁₋₄alkylene–OH;
- D, at each occurrence, is independently a cyclic dinucleotide;
- L¹, at each occurrence, is independently a linker;
- m, at each occurrence, is independently 1, 2, or 3; and
- p, at each occurrence, is independently 0, 1, or 2.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, of formula (I-A)



(I-A).


3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^{1a} is hydrogen.
4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^{1a} is C_{1-4} alkyl.
5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^{1a} is CH_3 .
6. The compound of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^{1b} is hydrogen.
7. The compound of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^{1b} is $C(O)N(R^{1c})-C_{1-6}$ alkylene- CO_2H .
8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R^{1b} is $C(O)N(R^{1c})CH_2CO_2H$.
9. The compound of any of claims 1-5 or 7-8, or a pharmaceutically acceptable salt thereof, wherein R^{1c} is hydrogen.
10. The compound of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^{1b} is $C(O)OH$.

11. The compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof,




wherein D, at each occurrence, is independently a nucleobase and X is O or S.

12. The compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein:




D' is a cyclic dinucleotide payload moiety.

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein the




cyclic dinucleotide payload moiety is

14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein the




cyclic dinucleotide payload moiety is


or




15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of




TCO-ADU-S100




TCO-2'3'-cGAMP



ADU-S100-TCO-Acid




ADU-S100-TCO-Glycine




2'3'-cGAMP-TCO-Acid

, or



2'3'-cGAMP-TCO-Glycine

16. A pharmaceutical composition comprising the compound of any of claims 1-15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. A pharmaceutical combination comprising a compound of any of claims 1-15, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 16, and a therapeutic support composition for use in the treatment of cancer; or for use in enhancing or eliciting an immune response, the therapeutic support composition comprising a biocompatible support and a tetrazine-containing group of formula



wherein

R^{20} is selected from the group consisting of hydrogen, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, cycloalkenyl, CF_3 , CF_2 -

R', NO₂, OR', SR', C(=O)R', C(=S)R', OC(=O)R''', SC(=O)R''', OC(=S)R''', SC(=S)R''', S(=O)R', S(=O)₂R''', S(=O)₂NR' R'', C(=O)O-R', C(=O)S-R', C(=S)O-R', C(=S)S-R', C(=O)NR'R'', C(=S)NR' R'', NR'R'', NR'C(=O)R'', NR'C(=S)R'', NR'C(=O)OR'', NR'C(=S)OR'', NR'C(=O)SR'', NR'C(=S)SR'', OC(=O)NR'R'', SC(=O)NR'R'', OC(=S) R'R''', SC(=S)R'R'', NR'C(=O)NR''R'', and NR'C(=S)NR''R'';

R' and R'' at each occurrence are independently selected from hydrogen, aryl and alkyl;


R''' at each occurrence is independently selected from aryl and alkyl;

R³⁰ is halogen, cyano, nitro, hydroxy, alkyl, haloalkyl; alkenyl, alkynyl, alkoxy; halalkoxy; heteroalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;


R^a, R^{31a} and R^{31b} are each independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl; and t is 0, 1, 2, 3, or 4.

18. The pharmaceutical combination of claim 17, wherein the tetrazine-containing group is linked or directly bonded to a hyaluronic acid biocompatible support.

19. The pharmaceutical combination of claim 17, wherein the therapeutic support composition comprises substituted hyaluronic acid units of formula (II),




(II)




wherein G² is ; and

R²² is a linker of 1 to 100 linking atoms.

20. The pharmaceutical combination of claim 19, wherein:



21. The pharmaceutical combination of claim 19, wherein



R^{20} is hydrogen or C_{1-4} alkyl.


22. The pharmaceutical combination of any of claims 17-21, wherein the use is for treating or preventing a cancer.

23. The pharmaceutical combination of claim 22, wherein the cancer is a melanoma, renal cancer, prostate cancer, ovarian cancer, breast cancer, glioma, lung cancer, soft tissue carcinoma, soft tissue sarcoma, osteosarcoma, or pancreatic cancer.

24. The pharmaceutical combination of claim 22 or 23, wherein the cancer is a solid tumor.

25. The pharmaceutical combination of claim 22 or 23, wherein the cancer is a soft tissue sarcoma.

26. The pharmaceutical combination of claim 25, wherein the soft tissue sarcoma is a fibrosarcoma, rhabdomyosarcoma, or Ewing's sarcoma.
27. The pharmaceutical combination of any of claims 17-21, wherein the use is for enhancing or eliciting an immune response.
28. The pharmaceutical combination of claim 27, wherein the immune response is an increase in one or more of leukocytes, lymphocytes, monocytes, and eosinophils.
29. The pharmaceutical combination of any of claims 17-28, further comprising an additional therapeutic agent selected from the group consisting of an anticancer agent, an immune checkpoint inhibitor, or a compound of formula (I-B), or a pharmaceutically acceptable salt thereof,




(I-B)

wherein

D^1 , at each occurrence, is independently a payload selected from an anticancer drug payload, a microbial immunosuppressive drug payload, an anti-restenosis drug payload, antibiotic drug payload, antifungal drug payload, antiviral drug payload, anti-inflammatory/anti-arthritis drug payload, a corticosteroid drug payload, and an immunosuppressant drug payload; and

R^{1a} , R^{1b} , L^1 , p , and m are as defined in any of claims 1-11.

30. The pharmaceutical combination of claim 29, wherein p is 0; m is 1; and $-\text{L}^1-$ is



31. The pharmaceutical combination of claim 29 or 30, wherein the anticancer drug is doxorubicin.
32. A kit comprising the compound of any of claims 1-15, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 16, and instructions for use thereof.
33. The kit of claim 32, further comprising the therapeutic support composition as defined in any of claims 19-23.
34. The kit of claim 32 or 33, further comprising the compound of formula (I-B), as defined in any of claims 29-31.